Back Edwards, K, Li, X, Linvay, I (1 April 2023) 'Clinical and safety outcomes with GLP-1 receptor agonists and SGLT2 inhibitors in type 1 diabetes: A real-world study', The Journal of Clinical Endocrinology & Metabolism , 108/ 4, 92030
Blue Cross and Blue Shield Association may cover Zepbound, but the coverage of this prescription medication will vary based on your specific pharmacy benefits
This covers consultation with a licensed medical provider, the compounded medication at appropriate doses, all injection supplies (syringes, needles, alcohol pads, sharps container), cold-chain shipping to maintain medication stability, monthly follow-up appointments and dose adjustments, and ongoing access to medical support
doi: 10.1097/MD.0000000000007638 114 WangB.LiR.LuZ.HuangY